2022
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Intranasal Zavegepant in Healthy Adults (S31.004)
Bertz R, Donohue M, Madonia J, Bhardwaj R, Stringfellow J, Anderson M, Stock D, Morris B, Coric V, Croop R. Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Intranasal Zavegepant in Healthy Adults (S31.004). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.1003.Peer-Reviewed Original ResearchMultiple ascending dosesPharmacokinetics of SingleAscending dosesHealthy adultsTolerabilityPharmacokineticsDoses
2020
Phase 1 and 2 Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose Rimegepant as Compared to the Predicted Clinically Efficacious Dose Range (2145)
Conway C, Dubowchik G, Croop R, Coric V. Phase 1 and 2 Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose Rimegepant as Compared to the Predicted Clinically Efficacious Dose Range (2145). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2145.Peer-Reviewed Original ResearchEfficacious dose rangePharmacokinetics of SingleDose rangePhase 1TolerabilityPharmacokineticsRimegepant